Conference Presentations
Educational Symposiums
-
S6 : EDUCATIONAL SYMPOSIUM: EVALUATIONS ON THE HEALTH TECHNOLOGY ASSESSMENT ERA IN JAPAN – FROM GOVERNMENTAL, ACADEMIC, AND PHARMACEUTICAL PERSPECTIVES
Presentation
Ataru Igarashi
PhD , Associate Professor, University of Tokyo, Department of Drug Policy and Management, Tokyo, Japan
-
S7 : EDUCATIONAL SYMPOSIUM: VALUE-BASED DECISION MAKING IN DEVELOPING COUNTRIES: MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR OFF-PATENT PHARMACEUTICALS
Presentation
Anke-Peggy Holtorf
PhD, MBA , Managing Director, GmbH, Health Outcomes Strategies, Basel, Switzerland
Kalman Emry Wijaya
PharmD., MBA , Global Market Access and Policy Sr. Manager, Abbott Products Operations AG, Global Market Access, Allschwil, Switzerland
Diana Brixner
PhD, RPh, FAMCP , Professor, Department of Pharmacotherapy, University of Utah College of Pharmacy,, University of Utah,, Executive Director, Pharmacotherapy Outcomes Research Center, and Director of Outcomes,, Salt Lake City,, USA
Zoltan Kalo
PhD , Professor of Health Economics, Eötvös Loránd University (ELTE), 2) Syreon Research Institute, Budapest, Hungary
Nikos Maniadakis,
Professor , Director, Alternate Dean, National School of Public Health,, Department of Health Services Organization & Management, Athens, Greece
-
S8 : EDUCATIONAL SYMPOSIUM: CHALLENGES AND OPPORTUNITIES IN VALUE ASSESSMENT OF INNOVATIVE BIOLOGIC MEDICINES
Presentation
Presentation
Marty Jovic,
MS , Partner, PricewaterhouseCoopers Consulting (Australia) Pty Limited, Barangaroo, Australia
Jinxi Ding
PhD, Professor and Vice Dean, , China Pharmaceutical University, School of International Pharmaceutical Business, , Nanjing, China
PLENARY SESSIONS
-
PL1 : Transforming Healthcare and Leveraging Digital Health for Better Health in Asia-Pacific
Presentation
Presentation
Presentation
Erwin Loh
MBBS, LLB(Hons), MBA, MHSM, PhD , Executive Director, Chief Medical Officer, Monash Health, Innovation, Patient Safety & Experience, Melbourne, Australia
Gabe Rijpma
Senior Director, Microsoft Asia, Health and Social Services, Auckland, New Zealand
Polawat Witoolkollachit
MD, Director, Ministry of Public Health (MOPH), Information Technology and Communication, Bangkok, Thailand
Lou Huei-Xin
PharmD, MSc (Clinical Pharm) , Director, Ancillary Care, Integrated Health Information Systems Pte Ltd, Head, National Pharmacy Program Management Office, Ministry of Health, Singapore, Singapore
-
PL2 : Real World Evidence in Asia-Pacific: Are We Ready? Is It Helpful for Decision Makers?
Presentation
Presentation
Presentation
Bart Barefoot
Director & VEO , GlaxoSmithKline, Real World Evidence Policy and Advocacy, Value Evidence and Outcomes (VEO), Global Medical, London, UK
Kinwei Arnold Chan
MD, ScD, FISPE , Director, Health Data Research Center, National Taiwan University, National Taiwan University Hospital, Department of Medical Research, and Director, Clinical Trial Center, Taipei, Taiwan
Manabu Akazawa
PhD, MPH , Professor, Meiji Pharmaceutical University, Public Health and Epidemiology Department, Tokyo, Japan
Xin Sun
PhD , Professor & Director, Sichuan University, Chinese Evidence-Based Medicine Center, West China Hospital, Chengdu, China
-
PL3 : Risk Sharing Agreements: Country Experiences, Challenges, and Lessons Learned
Presentation
Presentation
Presentation
Jang Sae Rak
Deputy Director, Health Insurance Review and Assessment Service, Pharmaceutical Listing Division, Pharmaceutical Benefit Department, Seoul, South Korea
Jörg Mahlich
PhD, Head, Health Economics and Outcomes Research, Janssen Pharmaceutical, Formal Director, Health Economics in Janssen Japan, Neuss, Germany
Elizabeth de Somer
Director, Medicines Australia, Policy & Research and Interim Chief Executive Officer, Canberra, Australia
Gergana Zlateva
PhD, Vice President, Pfizer Inc., Global Market Access-Oncology, Global Health & Value, New York, USA
ISSUE PANEL PRESENTATIONS
-
IP1 : COST VS VALUE: WHAT IS THE FAIR PRICE OF A DRUG?
Presentation
Presentation
Presentation
Mark Sculpher
PhD, University of York, Centre for Health Economics, York, United Kingdom
Takashi Fukuda
PhD, National Institute of Public Health, Wako, Japan
Christoph Glaetzer
Dipl. Kfm, Janssen, Pharmaceutical Companies of Johnson&Johnson, NJ, USA
-
IP10 : WHAT EVIDENCE SHOULD BE USED TO QUANTIFY COST-EFFECTIVENESS THRESHOLDS FOR DECISION-MAKING IN THE ASIA PACIFIC REGION?
Presentation
Presentation
Presentation
Mark Sculpher
PhD, University of York, Centre for Health Economics, York, United Kingdom
Yot Teerawattananon
PhD, Health Intervention and Technology Assessment Program (HITAP), Muang, Nonthaburi, Thailand
Jonathan Karnon
PhD, The University of Adelaide, School of Public Health, Adelaide, Australia
-
IP11 : A TRIAL HTA INTRODUCTION IN JAPAN: LEARNING AND WAY FORWARD
Presentation
Takashi Fukuda
PhD, National Institute of Public Health, Department of Health and Welfare Services, Wako, Japan
-
IP12 : HOW TO MEASURE AND VALUE HEALTH BENEFITS TO FACILITATE PRIORITY SETTING FOR PEDIATRIC POPULATION? DEVELOPMENT AND APPLICATION ISSUES
Presentation
Presentation
Presentation
Gang Chen
PhD, MSc, BMed, Monash University, Centre for Health Economics, Monash Business School, Melbourne, Australia
Nan Luo
PhD, National University of Singapore, Saw Swee Hock School of Public Health, Singapore, Singapore
Ruoyan Gai
PhD, National Center for Child Health and Development of Japan, Division of Policy Evaluation, Department of Health Policy and Chief, Division of Health Technology Assessment, Department of Clinical Epidemiology, Tokyo, Japan
-
IP13 : MCDA IN HTA: WOULD MCDA BE A VALUABLE ADDITION TO THE CURRENT JAPANESE HTA SYSTEM?
Presentation
Presentation
Presentation
Yot Teerawattananon
Dr., HUTAP, Department of Health, Ministry of Public Health, Nonthaburi, Thailand
Ataru Igarashi
PhD, University of Tokyo, Department of Drug Policy and Management, Tokyo, Japan
Omer Saka
MD, MSc, Deloitte Belgium, Health Economics and Outcomes Research, Zaventem, Belgium
-
IP14 : MANAGED ENTRY SCHEMES: HYPE VS. REALITY
Presentation
Presentation
Presentation
Jeonghoon Ahn
PhD, Ewha Womans University, Department of Health Convergence, Seoul, Korea, Republic of (South)
Greg Cook
PhD,, Bristol Myers Squibb, Health Economics, Mulgrave, Australia
Jonathan Karnon
PhD, The University of Adelaide, School of Public Health, Adelaide, Australia
-
IP15 : CURRENT PRACTICES AND PROSPECTS IN MANAGING REIMBURSEMENT IN ASIA PACIFIC AND EUROPE: WHAT WE CAN DO MORE TO BRIDGE THE EXPERIENCE AND EXPECTATION?
Presentation
Adrian Griffin
MSc, Johnson & Johnson, HTA & Reimbursement Policy, Buckinghamshire, United Kingdom
Nathorn Chaiyakunapruk
Pharm.D., Ph.D., Naresuan University, Center of Pharmaceutical Outcomes Research (CPOR), Department of Pharmacy Practice, Phitsanulok, Thailand
Zhao Kun
MD, PhD, MHSc, Division of Health Technology, Beijing, China
Onozaki Kohei
MS, Health and Global Policy Institute, Tokyo, Japan
-
IP16 : DOES TRANSPARENCY HELP OR HINDER EMERGING HTA SYSTEMS?
Presentation
Fiona Pearce
MPH, Agency for Care Effectiveness, Ministry of Health, Singapore, Singapore, Singapore
Wrik Ghosh
BA, MSc, Costello Medical, Singapore, Singapore
Thomas Butt
PhD, Peking University, China Center for Health Economic Research, Beijing, China
Brenda Pote
MSc, Roche Singapore Pte. Ltd., Singapore, Singapore
-
IP17 : HOW COLLABORATIVE CAN COMPANIES BE IN DEVELOPING EVIDENCE TO SUPPORT MARKET ACCESS?
Presentation
Anthony Hatswell
MSc, Delta Hat, Nottingham, United Kingdom
Josie Godfrey
BA, MA, MA, JG Zebra Consulting, London, United Kingdom
Klair Bayley
BSc, Save Our Sons Duchenne Foundation, Hurlstone Park, Australia
David Pearce
BPharm, MSc, Takeda Pharmaceuticals, Pricing Market Access and Health Economics, Singapore, Singapore
-
IP18 : HOW TO DEAL WITH MODEL UNCERTAINTY AT THE PLANNING STAGE OF COST-EFFECTIVENESS ANALYSIS?: TIPS FROM GLOBAL EXPERIENCES
Presentation
Presentation
Presentation
Joe Caputo
BSc., Vista Health Pte Ltd., Singapore, Singapore
Emiko Yoshida
MSc., Healthcare to All, Tokyo, Japan
George Papadopoulos
BSc(Hons), GradDipEpi, Lucid Health Consulting Pty. Ltd., NSW, Australia
-
IP19 : OVERDIAGNOSIS AND ITS EXCESS COST FOR CANCER SCREENING
Presentation
Presentation
Presentation
Presentation
Amy Ming-Fang Yen
PhD, Taipei Medical University, Taipei, Taiwan
Tony Hsiu-Hsi Chen
PhD, National Taiwan University, Taipei, Taiwan
Sherry Yueh-Hsia Chiu
PhD, Chang Gung University, Taoyuan, Taiwan
Chisato Hamashima
MD, Teikyo University, Faculty of Medical Technology, Tokyo, Japan
-
IP2 : OPPORTUNITIES AND CHALLENGES IN INTERNATIONAL HARMONIZATION OF HTA OF MEDICAL DEVICES – GAPS BETWEEN EUROPEAN AND ASIAN COUNTRIES
Presentation
Presentation
Presentation
Sukyeong Kim
PhD, RPh, MPH, National Evidence-Based Healthcare Collaborating Agency (NECA), Seoul, Korea, Republic of (South)
Ataru Igarashi
PhD, University of Tokyo, Department of Drug Policy and Management, Tokyo, Japan
Rosanna Tarricone
MSc, PhD, Bocconi University, SDA Bocconi School of Management, Milano, Italy
-
IP20 : DISCRETE CHOICE EXPERIMENTS AS A MEASURE OF SOCIAL VALUE AND PREFERENCES: APPLICATION TO POLICY MAKING IN ASIA-PACIFIC
Presentation
Presentation
Presentation
Stephen Goodall
BSC, MSC, PhD, University of Technology Sydney, Centre for Health Economics Research and Evaluation, Sydney, Australia
Ruoyan Gai
PhD, National Center for Child Health and Development of Japan, Division of Policy Evaluation, Department of Health Policy and Chief, Division of Health Technology Assessment, Department of Clinical Epidemiology, Tokyo, Japan
Brendan Mulhern
MRes, University of Technology Sydney, Centre for Health Economics Research and Evaluation, Sydney, Australia
-
IP21 : DOES OVERSEAS EXPERIENCE OF MANAGED ENTRY AGREEMENTS INFORM THE NEW JAPANESE PRICING SCHEME FOR MEDICAL DEVICES?
Presentation
Presentation
Presentation
Kosuke Kato
PhD, American Medical Devices and Diagnostics Manufacturers’ Association (AMDD), Nakano-ku, Japan
Makoto Tamura
PhD, International University of Health and Welfare, Ohtawara City, Japan
Michael Drummond
MCom, DPhil, University of York, Centre for Health Economics, York, United Kingdom
-
IP3 : HOW WILL PATIENT CENTRICITY BE CAPTURED IN THE JAPANESE HTA AND HEALTHCARE REFORM?
Presentation
Presentation
Presentation
Adrian Towse
MA, MPhil, Office of Health Economics, London, United Kingdom
Shunya Ikeda
MD, International University of Health and Welfare, Narita city, Japan
Durhane Wong-Rieger
BA MA PHD, Canadian Organization for Rare Disorders, Toronto, Canada
-
IP4 : GLOBAL ALIGNMENT ON APPROACHES TO USE OF REAL WORLD EVIDENCE IN DECISION MAKING
Presentation
Nicholas Crabb
PhD, NICE, Scientific Affairs, Manchester, United Kingdom
David Pearce
BPharm, MSc, Takeda Pharmaceuticals, Pricing Market Access and Health Economics, Singapore, Singapore
Rob Thwaites
MA, MCom, Takeda, London, United Kingdom
Shunichi Fukuhara
MD, PhD, Kyoto University, Kyoto, Japan
-
IP5 : BETTER THE DEVIL YOU KNOW? QALYs AND THEIR ALTERNATIVES IN DRUG REIMBURSEMENT DECISION-MAKING
Presentation
Presentation
Presentation
Danny Liew
MBBS (Hons), BMedSc, FRACP, PhD, CertHealthEcon, Monash University, Melbourne, Australia
J. Jaime Caro
MDCM, McGill University, Medicine, Epidemiology, and Biostatistics, Montreal, Canada
Mark Sculpher
PhD, University of York, Centre for Health Economics, York, United Kingdom
-
IP6 : WHAT IS THE HTA IMPLICATION IN PATIENT ACCESS AND WHAT ARE THE CRITICAL FACTORS TO MAKE A BALANCE FOR INNOVATIVE MEDICINES? - 10 YEARS EXPERIENCES WITH HTA IN KOREA
Presentation
Presentation
Eui-Kyung Lee
PhD, School of Pharmacy, Sungkyunkwan University, Suwon, Korea, Republic of (South)
Sungju Kim
PhD, Novartis Korea, Patient Access, Seoul, Korea, Republic of (South)
-
IP7 : WHAT IS THE VALUE OF RARE DISEASE THERAPIES FOR DEVELOPING HEALTHCARE SYSTEMS?
Presentation
Ran Geng
BSE, Venture Capital, Beijing, China
Thomas Butt
PhD, Peking University and University College London, China Center for Health Economic Research, Beijing, China
Kevin Huang
-, China Organization for Rare Disorders, Beijing, China
Gordon G Liu
PhD., National School of Development, Peking University, Beijing, China
-
IP8 : GLOBAL HORIZON SCANNING: POLICY IMPLICATIONS AND PRACTICALITIES
Presentation
Karen Facey
PhD, University of Edinburgh, Usher Institute of Population Health Sciences and Informatics, Drymen, United Kingdom
Kun Zhao
MD, MHSci, China National Health Development Research Center, National Health and Family Planning Commission (NHFPC), China National Health Development Research Center, NHC, Beijing, China
Sukyeong Kim
PhD, RPh, MPH, National Evidence-based Health Care Collaborating Agency (NECA), Evidence-based Research Department, Seoul, Korea, Republic of (South)
Franz Pichler
PhD, Eli Lilly, Global Public Policy, Sydney, Australia
WORKSHOP PRESENTATIONS
-
W1 : HEALTH ECONOMIC EVALUATIONS TO SUPPORT PUBLIC HEALTH DECISION-MAKING IN VACCINES: ARE COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT ANALYSIS SUFFICIENT TO ANSWER THE POLICY QUESTIONS?
Presentation
Presentation
Sharon Zhang
Ph D, GSK Vaccines, Singapore, Singapore
Baudouin Standaert
MD, PhD, GSK Vaccines, Wavre, Belgium
-
W13 : MODELLING DISEASE PROGRESSION AND ECONOMIC OUTCOMES OF DEMENTIA INTERVENTIONS: EXPLORING OPTIONS FOR A COMPLEX HEALTH PROBLEM
Presentation
Brendan Mulhern
MRes, University of Technology Sydney, Centre for Health Economics Research and Evaluation, Sydney, Australia
Tracy Comans
PhD. B.Econ(Hons) B.Phty, University of Queensland, Centre for Health Services Research, Brisbane, Australia
Jasmine Pwu
PhD, MOHW, Taipei, Taiwan
Kim-Huong Nguyen
PhD, University of Queensland, Centre for Health Service Research, Brisbane, Australia
-
W14 : DELAYED ACCESS FOR PATIENTS WITH RARE DISEASES IN ASIA PACIFIC: FINDING A SOLUTION THAT WORKS
Presentation
Shanlian Hu
MD, MSc, Shanghai Health Development Research Center, Shanghai, China
Ming-Chin Yang
Dr.PH, National Taiwan University, Public Health, Taipei, Taiwan
Annabel Griffiths
PhD, Costello Medical, Lawrenceville, United Kingdom
Bertram Haeussler
MD, IGES Institut GmbH, Berlin, Germany
-
W15 : DYNAMIC ADJUSTMENT MECHANISM FOR NATIONAL DRUG FORMULARY: INTERNATIONAL EXPERIENCES AND THE DEVELOPMENT IN CHINA
Presentation
Presentation
Presentation
Fei-Li Zhao
PharmD, MS, PhD, University of Newcastle (UoN), Callaghan, Australia
Jiuhong Wu
PhD, PharmD, The 306th Hospital of PLA, Beijing, China
Feng Xie
BSc MSc PhD, McMaster University, Department of Health Research Methods, Evidence, and Impact (formerly Clinical Epidemiology and Biostatistics), Hamilton, Canada
-
W16 : THE APPLICATION OF INDICATION BASED PRICING TO REGENERATIVE MEDICINE THERAPIES: AN INTERACTIVE WORKSHOP
Presentation
Diana Brixner
PhD, RPh, FAMCP, University of Utah, Executive Director, Pharmacotherapy Outcomes Research Center, and Director of Outcomes, Salt Lake City, USA
Michael Drummond
MCom, DPhil, University of York, Centre for Health Economics, Heslington, York, United Kingdom
Masayuki Yamato
PhD, Tokyo Women's Medical University, Institute of Advanced Biomedical Engineering and Science, Tokyo, Japan
Mime Egami
BA, University of Utah, Department of Pharmaceutics and Pharmaceutical Chemistry, Executive Director, Cell Sheet Tissue Engineering Regenerative Medicine Initiatives, Tokyo, Japan, Salt Lake City, USA
-
W17 : HOW E-CONNECTED MEDICINE WILL CHANGE THE VALUE OF PHARMACEUTICALS
Presentation
Presentation
Presentation
Presentation
Taishiro Kishimoto
MD, PhD, Keio University School of Medicine, Tokyo, Japan
Ataru Igarashi
PhD, University of Tokyo, Graduate School of Pharmaceutical Sciences, Department of Health Economics and Outcomes Research, Tokyo, Japan
Yasuko Aitoku
BS, Bayer Yakuhin Ltd., Osaka, Japan
Mondher Toumi
MD, PhD, MSc, Aix-Marseille University, Faculté de Médecine, Laboratoire de Santé Publique, Marseille, France
-
W18 : VALUE OF INFORMATION ANALYSIS: PRINCIPLES, APPLICATIONS AND GOOD PRACTICE RECOMMENDATIONS
Presentations
Lotte Steuten
PhD, MSc, Fred Hutchinson Cancer Research Center, Seattle, USA
Paul Scuffham
PhD, Griffith University, Centre for Applied Health Economics, Brisbane, Australia
Haitham Tuffaha
BPharm, MBA, MSc, PhD, Griffith University, Centre for Applied Health Economics, Brisbane, Australia
-
W2 : THE EQ-5D-5L INSTRUMENT: PAST, PRESENT AND FUTURE
Presentation
Mark Oppe
PhD, EuroQol Research Foundation, Rotterdam, Netherlands
Nan Luo
PhD, National University of Singapore, Saw Swee Hock School of Public Health, Singapore, Singapore
Kim Rand
PhD, University of Oslo, Department of Health Management and Health Economics, Oslo, Norway
-
W4 : THE NEW WAVE IN REAL WORLD EVIDENCE – INTEGRATED DATASETS
Presentation
Tom Haskell
BS, Kantar Health, Global Operations, Horsham, USA
Ataru Igarashi
PhD, University of Tokyo, Graduate School of Pharmaceutical Sciences, Department of Health Economics and Outcomes Research, Tokyo, Japan
Yuji Yamamoto
M.D. MBA, MinaCare Co. Ltd., Tokyo, Japan
Vince Grillo
MBA, PhD, Kantar Health, Singapore, Singapore
-
W5 : JAPANESE HTA AND PRICING: CURRENT METHODS AND FUTURE POTENTIAL
Presentation
Presentation
Isao Kamae
MD, DrPH, The Univeristy of Tokyo, Graduate School of Public Policy, Tokyo, Japan
Makoto Kobayashi
PhD, M.Eng., CRECON Medical Assessment Inc., Tokyo, Japan
-
W6 : RESPONSE BASED COST-EFFECTIVENESS MODELING IN IMMUNO-ONCOLOGY
Presentation
Presentation
Presentation
Noemi Muszbek
MSc, Evidera, London, United Kingdom
Joe Zhuo
PhD, Merck KGaA, Billerica, USA
J. Jaime Caro
MDCM, McGill University, Medicine, Epidemiology, and Biostatistics, Montreal, Canada
-
W7 : HOW CAN HTA METHODS BE ADAPTED TO MEET THE SPECIAL CHARACTERISTICS OF MEDICAL DEVICES?
Presentation
Presentation
Presentation
Michael Drummond
MCom, DPhil, University of York, Centre for Health Economics, York, United Kingdom
Rei Goto
MD, PhD, Keio University, Graduate School of Business Administration, Yokohama, Japan
Rosanna Tarricone
MSc, PhD, Bocconi University, SDA Bocconi School of Management, Milano, Italy
-
W9 : BRIDGING THE GAP BETWEEN EFFICACY AND EFFECTIVENESS: USING BOTH REAL-WORLD AND TRIAL-BASED EVIDENCE TO IMPROVE CLINICAL DECISION MAKING
Presentation
Fei-Yuan Hsiao
PhD, National Taiwan University, Graduate Institute of Clinical Pharmacy, Taipei, Taiwan
Bor-Sheng Ko
MD, PhD, National Taiwan University Hospital, BMT Unit and Hematology Division, Department of Internal Medicine, Taipei, Taiwan
Ming-Hui Tai
PhD, Amgen, Global Health Economics, Thousand Oaks, USA
Han-I Wang
PhD, University of York, Epidemiology & Cancer Statistics Group, York, United Kingdom
ISPOR FORUMS
-
F2 : HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES IN ASIA PACIFIC
Presentation
Presentation
Presentation
Presentation
Presentation
Devarshi Bhattacharyya
MSc, MPH, Kalam Institute of Health Technology (KIHT), Visakhapatnam, India
Richard J Milne
BSc(Hons), MSc, PhD, University of Auckland, Health Outcomes Associates Ltd, and Associate Professor, School of Population Health, Auckland, New Zealand
Alexandr Kostyuk
MD, PhD, Ministry of Health and Social Development, Clinical Excellence at Republican Center for HealthCare Development and Chairman of the HTA Expert Group at Joint Committee for Quality Healthcare Services, Astana, Kazakhstan
Wudong Guo
PhD, National Health Commission, China National Health Development Research Center, Beijing, China
Sukyeong Kim
PhD, RPh, MPH, National Evidence-based Health Care Collaborating Agency (NECA), Evidence-based Research Department, Seoul, Korea, Republic of (South)
-
F3 : ISPOR SCIENTIFIC AND HEALTH POLICY GROUPS
Presentation
Clarissa Cooblall
MPH, ISPOR, Scientific & Health Policy Initiatives, Lawrenceville, USA